We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Name | Symbol | Market | Type |
|---|---|---|---|
| AstraZeneca PLC | NASDAQ:AZN | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 75.76 | 75.48 | 75.99 | 0 | 01:00:00 |
From May 2021 to May 2024
By Anthony O. Goriainoff
NetScientific PLC said Monday that its subsidiary ProAxsis Ltd. has entered into an exclusive licensing agreement with AstraZeneca PLC for an antibody test for SARS-CoV-2, the virus which causes Covid-19.
The London-listed life-sciences company said ProAxsis will complete the validation and global commercialization of a SARS-CoV-2 serology enzyme-linked immunosorbent assay developed at AstraZeneca.
"This highly sensitive and specific blood test makes use of simple and convenient fingerstick sample collection that will be well suited to large scale deployment and has the potential to play an important role in antibody analyses in large populations," AstraZeneca said.
The company said AstraZeneca will receive a royalty fee on future global net sales of the assay.
"The assay could if fully validated potentially attract a substantial market. It is envisaged that the validation and initial commercialization can be achieved largely from ProAxsis' existing resources," Chief Executive Ilian Iliev said.
Write to Anthony O. Goriainoff at anthony.orunagoriainoff@dowjones.com
(END) Dow Jones Newswires
June 07, 2021 02:50 ET (06:50 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year AstraZeneca Chart |
1 Month AstraZeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
